On the morning of March 12, SiliDi Pharmaceutical Co., Ltd. (01244.HK) opened more than 7% higher. As of press time, it rose 3.33%. On the news front, SiliDi Pharmaceutical Co., Ltd. recently announced that its layout of "AI+mRNA" tumor vaccine has made a breakthrough. The company's key component of lipid nanoparticles (LNP) for nucleic acid drug delivery, ionizable cationic lipids, has recently applied for PCT patents. It is reported that by using AI to design and screen hundreds of lipid compounds, an ionizable cationic lipid research and development platform has been established for different cell types and organ targeting, and the development of self-developed mRNA tumor vaccine projects has been efficiently coordinated, breaking through delivery technology barriers, improving drug targeting, solving problems such as non-specific tissue distribution, and improving drug development efficiency. SiliDi Pharmaceutical Co., Ltd. is an innovative drug company that has entered the commercialization stage and focuses on the field of chronic tumor treatment.

In terms of industry dynamics, the application of AI technology in the medical industry is continuing to expand. Specifically, in the early stage of research and development of innovative drugs, AI has greatly shortened the research and development cycle and reduced research and development costs through functions such as screening and target prediction, and has become an important means for pharmaceutical companies to reduce costs and increase efficiency.

In the operation of medical institutions, with the help of AI's image recognition, data analysis and other technologies, the efficiency and accuracy of diagnosis can be effectively improved, and the allocation of medical resources can be optimized.

In the field of vaccine research and development, AI technology should not be underestimated. Previously, Oracle's chairman Larry Ellison said that artificial intelligence can not only play a key role in early screening of tumors, but also develop personalized tumor mRNA vaccines for each cancer patient, and with the help of AI, such tailor-made mRNA vaccines can be manufactured through automated systems within 48 hours.

Guo Tao, a senior artificial intelligence expert, said in an interview with the reporter of the Science and Technology Innovation Board Daily that in the field of "AI+Vaccine", AI technology is mainly used for vaccine design, drug screening, clinical trial optimization and the formulation of personalized medical plans. For example, through deep learning algorithms, researchers can quickly analyze large amounts of biological data, identify potential vaccine targets, and accelerate the vaccine design process. In addition, AI can also help predict the safety and effectiveness of vaccines and improve R&D efficiency.

"Most of these applications are still in the research or pilot stage, and there is still a long way to go before they can be widely popularized and applied." Guo Tao further added, "But with the improvement of computing power and the advancement of algorithms, AI will be able to more accurately predict the effects and side effects of vaccines and achieve more personalized treatment plans. In the future, as technology matures and costs decrease, AI is expected to become an important auxiliary tool in vaccine development and medicine."

https://finance.eastmoney.com/a/202503123343597737.html